Key clinical point: The late health status benefits seen with transcatheter aortic valve replacement (TAVR) were driven by a difference in the proportion of patients who experienced a large (20-point or greater) improvement in the Kansas City Cardiomyopathy Questionnaire–Overall Summary score.
Major finding: The researchers observed a persistent, although attenuated, benefit of TAVR over surgical aortic valve replacement in disease-specific health status at 6 and 12 months (mean difference in Kansas City Cardiomyopathy Questionnaire–Overall Summary of 2.6 and 1.8 points respectively; P less than .04 for both).
Study details: An analysis of 449 low-risk patients with severe aortic stenosis who were assigned to transfemoral TAVR using a balloon-expandable valve, and 449 who were assigned to surgery in the PARTNER 3 trial.
Disclosures: The PARTNER 3 quality of life substudy was funded by Edwards Lifesciences. Dr. Baron disclosed research funding and advisory board compensation from Boston Scientific and consulting fees from Edwards Lifesciences.
Baron SJ. TCT 2019, Late-breaking Trials Session.